Allopurinol and Haematological malignancy - a phase IV clinical study of FDA data

Summary:

Haematological malignancy is reported as a side effect among people who take Allopurinol (allopurinol), especially for people who are male, 60+ old, also take Prednisone, and have Idiopathic thrombocytopenic purpura.

The phase IV clinical study analyzes which people have Haematological malignancy when taking Allopurinol. It is created by eHealthMe based on reports of 188,106 people who have side effects when taking Allopurinol from the FDA, and is updated regularly.

What is Allopurinol?

Allopurinol has active ingredients of allopurinol. It is often used in gout. eHealthMe is studying from 190,868 Allopurinol users. Check the latest studies of Allopurinol.

What is Haematological malignancy?

Haematological malignancy (cancer that affect blood, bone marrow, and lymph nodes) is found to be associated with 73 drugs and 351 conditions by eHealthMe. Check the latest studies of Haematological malignancy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 19, 2026

188,106 people reported to have side effects when taking Allopurinol.
Among them, 23 people (0.01%) have Haematological malignancy.

Could Allopurinol cause Haematological malignancy?

Among these 23 people:

What is the gender of people who have Haematological malignancy when taking Allopurinol? *

female: 16.67 %
male: 83.33 %

What is the age of people who have Haematological malignancy when taking Allopurinol? *

What are other drugs people take besides Allopurinol? *

What are other side effects people have besides Haematological malignancy? *

Thrombocytopenia (decrease of platelets in blood): 10 people, 43.48%
Fatigue (feeling of tiredness): 9 people, 39.13%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 8 people, 34.78%
Anaemia (lack of blood): 8 people, 34.78%
Therapeutic Response Decreased (less preventive response): 8 people, 34.78%
Weakness: 7 people, 30.43%
Splenomegaly (enlargement of spleen): 6 people, 26.09%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 6 people, 26.09%
Normochromic Normocytic Anaemia (forms of anaemia in which the average size and haemoglobin content of the red blood cells are within normal limits): 6 people, 26.09%
Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 21.74%

What are the existing conditions these people have? *

Idiopathic Thrombocytopenic Purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 11 people, 47.83%
Primary Myelofibrosis (primary disorder of the bone marrow): 3 people, 13.04%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 13.04%
Fluid Retention (an abnormal accumulation of fluid in the blood): 2 people, 8.70%
Haemochromatosis (body to absorb more iron than usual from food): 2 people, 8.70%
High Blood Pressure: 2 people, 8.70%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 8.70%
Anaemia (lack of blood): 2 people, 8.70%
Febrile/cold Agglutinins (antibodies makes red blood cells to clump together in hot and cold temperature): 2 people, 8.70%
Anorectal Abscess: 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Allopurinol and have Haematological malignancy?

- Check whether Haematological malignancy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Allopurinol:

Allopurinol (190,868 reports)

Browse all side effects of Allopurinol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haematological malignancy:

Haematological malignancy (73 drugs)

Browse all the conditions that are associated with Haematological malignancy:

Haematological malignancy (351 conditions)

Related publications that referenced our studies

Yava?o?lu I, Sarg?n G, Demirbulat A, "Carbamazepine and hematological malignancies", Turkish journal of haematology: official journal of Turkish Society of Haematology, 2013 Jan .
Yava?o?lu I, Sarg?n G, Demirbulat A, "Carbamazepine and hematological malignancies", Turkish journal of haematology: official journal of Turkish Society of Haematology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on allopurinol (the active ingredients of Allopurinol) and Allopurinol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.